Search Results - "Southwood, Taunton"

Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study by Davies, Rebecca, Southwood, Taunton R., Kearsley‐Fleet, Lianne, Lunt, Mark, Hyrich, Kimme L.

“…Objective The association between anti–tumor necrosis factor therapy and increased rates of infection is widely documented in adults with rheumatoid arthritis…”
Get full text

Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis by Kearsley-Fleet, Lianne, Baildam, Eileen, Beresford, Michael W, Douglas, Sharon, Foster, Helen E, Southwood, Taunton R, Hyrich, Kimme L, Ciurtin, Coziana

“…Abstract Objectives Clinicians concerned about long-term safety of biologics in JIA may consider tapering or stopping treatment once remission is achieved…”
Get full text

Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study by Kearsley-Fleet, Lianne, Davies, Rebecca, Lunt, Mark, Southwood, Taunton R, Hyrich, Kimme L

“…The objectives of this study were to investigate change in disease activity, and explore factors associated with response, in children with JIA over the…”
Get full text

Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra by Kearsley-Fleet, Lianne, Beresford, Michael W, Davies, Rebecca, De Cock, Diederik, Baildam, Eileen, Foster, Helen E, Southwood, Taunton R, Thomson, Wendy, Hyrich, Kimme L

“…Abstract Objectives To investigate real-world short-term outcomes among patients with systemic JIA starting tocilizumab or anakinra. Methods This analysis…”
Get full text

Paediatric rheumatic disease: Treatment of JIA in the biologic era: what are we waiting for? by Southwood, Taunton R

Get full text

Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers by Kearsley-Fleet, Lianne, Davies, Rebecca, Baildam, Eileen, Beresford, Michael W, Foster, Helen E, Southwood, Taunton R, Thomson, Wendy, Hyrich, Kimme L

“…The objectives of this study were to describe patients starting first-line biologics for JIA, to describe characteristics over time among patients starting…”
Get full text

Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins by Gardner-Medwin, Janet MM, Dolezalova, Pavla, Cummins, Carole, Southwood, Taunton R

“…The frequency and ethnic variation of Henoch-Schönlein purpura, Kawasaki disease, and rarer vasculitides during childhood are not well characterised. Our aim…”
Get full text

International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001 by PETTY, Ross E, SOUTHWOOD, Taunton R, SUAREZ-ALMAZOR, Maria E, WOO, Patricia, MANNERS, Prudence, BAUM, John, GLASS, David N, GOLDENBERG, Jose, XIAOHU HE, MALDONADO-COCCO, Jose, OROZCO-ALCALA, Javier, PRIEUR, Anne-Marie

Get full text

Treatment of JIA in the biologic era: what are we waiting for? by Southwood, Taunton R.

“…If the use of the right treatment at the right time might 'cure' juvenile idiopathic arthritis, how do we determine the optimum timing of biologic therapy? The…”
Get full text

Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom by Kearsley-Fleet, Lianne, Sampath, Sunil, McCann, Liza J, Baildam, Eileen, Beresford, Michael W, Davies, Rebecca, De Cock, Diederik, Foster, Helen E, Southwood, Taunton R, Thomson, Wendy, Hyrich, Kimme L

“…Abstract Objectives Rituximab (RTX) may be a treatment option for children and young people with JIA, although it is not licensed for this indication. The aim…”
Get full text

Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study by Kearsley-Fleet, Lianne, Hyrich, Kimme L, Davies, Rebecca, Lunt, Mark, Southwood, Taunton R

“…Children with JIA can experience delayed and restricted growth. The objectives of this study were to investigate the influence of etanercept (ETN) on vertical…”
Get full text

Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis by Kearsley-Fleet, Lianne, Vicente González, Laura, Steinke, Douglas, Davies, Rebecca, De Cock, Diederik, Baildam, Eileen, Beresford, Michael W, Foster, Helen E, Southwood, Taunton R, Thomson, Wendy, Hyrich, Kimme L

“…This analysis aims to calculate MTX monotherapy persistence and describe the occurrence of and factors associated with the occurrence of adverse drug reactions…”
Get full text

Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study by Kearsley-Fleet, Lianne, Baildam, Eileen, Beresford, Michael W, Douglas, Sharon, Foster, Helen E, Southwood, Taunton R, Hyrich, Kimme L

“…For cost-saving purposes, children and young people with juvenile idiopathic arthritis (JIA) are being switched (for non-medical reasons) from biological…”
Get more information

The Association of Intrapair Birth-Weight Differences With Internalizing and Externalizing Behavior Problems by Tore, Elena C., Antoniou, Evangelia E., Reed, Keith, Southwood, Taunton R., Smits, Luc, McCleery, Joseph P., Zeegers, Maurice P.

“…Problem behaviors are of increasing public health concern. Twin studies have revealed substantial genetic and environmental influences on children's behavior,…”
Get full text

Gestational Weight Gain by Maternal Pre-pregnancy BMI and Childhood Problem Behaviours in School-Age Years: A Pooled Analysis of Two European Birth Cohorts by Tore, Elena C., Antoniou, Evangelia E., de Groot, Renate H. M., Gielen, Marij, Godschalk, Roger W. L., Roumeliotaki, Theano, Smits, Luc, Southwood, Taunton R., Spaanderman, Marc E. A., Stratakis, Nikos, Vafeiadi, Marina, Chatzi, Vaia L., Zeegers, Maurice P.

“…Objectives Maternal pre-pregnancy weight is known to affect foetal development. However, it has not yet been clarified if gestational weight gain is associated…”
Get full text

Maternal pre-pregnancy weight and externalising behaviour problems in preschool children: a UK-based twin study by Antoniou, Evangelia E, Fowler, Tom, Reed, Keith, Southwood, Taunton R, McCleery, Joseph P, Zeegers, Maurice P

“…Objective To estimate the heritability of child behaviour problems and investigate the association between maternal pre-pregnancy overweight and child…”
Get full text

Striking intrafamilial phenotypic variability in Aicardi–Goutières syndrome associated with the recurrent Asian founder mutation in RNASEH2C by Vogt, Julie, Agrawal, Shakti, Ibrahim, Zala, Southwood, Taunton R., Philip, Sunny, MacPherson, Lesley, Bhole, Malini V., Crow, Yanick J., Oley, Christine

“…Aicardi–Goutières syndrome (AGS) is an encephalopathy of early childhood which is most commonly inherited as an autosomal recessive trait. The disorder…”
Get full text

Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients by Southwood, Taunton R, Foster, Helen E, Davidson, Joyce E, Hyrich, Kimme L, Cotter, Catherine B, Wedderburn, Lucy R, Hull, Richard G, Venning, Helen E, Rahman, Joy K, Cummins, Carole L

“…Since 2004, juvenile idiopathic arthritis (JIA) patients treated with etanercept and/or MTX have been monitored in the British Society for Paediatric and…”
Get full text

An empirical study on the preferred size of the participant information sheet in research by Antoniou, Evangelia E, Draper, Heather, Reed, Keith, Burls, Amanda, Southwood, Taunton R, Zeegers, Maurice P

“…BackgroundInformed consent is a requirement for all research. It is not, however, clear how much information is sufficient to make an informed decision about…”
Get full text

Using registries to identify adverse events in rheumatic diseases by Lionetti, Geraldina, Kimura, Yukiko, Schanberg, Laura E, Beukelman, Timothy, Wallace, Carol A, Ilowite, Norman T, Winsor, Jane, Fox, Kathleen, Natter, Marc, Sundy, John S, Brodsky, Eric, Curtis, Jeffrey R, Del Gaizo, Vincent, Iyasu, Solomon, Jahreis, Angelika, Meeker-O'Connell, Ann, Mittleman, Barbara B, Murphy, Bernard M, Peterson, Eric D, Raymond, Sandra C, Setoguchi, Soko, Siegel, Jeffrey N, Sobel, Rachel E, Solomon, Daniel, Southwood, Taunton R, Vesely, Richard, White, Patience H, Wulffraat, Nico M, Sandborg, Christy I

“…The proven effectiveness of biologics and other immunomodulatory products in inflammatory rheumatic diseases has resulted in their widespread use as well as…”
Get full text